India’s weight-loss price war begins as semaglutide patent expires

South China Morning PostCenter-RightEN 1 min read 100% complete by Vasudevan SridharanMarch 19, 2026 at 01:19 PM

AI Summary

short article 1 min

In India, a price war for weight-loss drugs is emerging as the patent for semaglutide expires. Individuals like Namita Joshi are using these medications, alongside diet and exercise, to combat obesity. Joshi spends approximately 30,000 rupees (US$322) monthly on the injections, which have already seen price reductions and are expected to become even more affordable. The medications are used to improve both physical and mental health. The availability of cheaper alternatives could make weight-loss treatments accessible to a broader segment of the population.

Key Entities & Roles

Key Player Opposition Context

Mumbai 60% India 70% Namita Joshi ×590%

Keywords

weight loss 100% semaglutide 80% weight-loss medication 70% obesity 60% price war 60% patent expiration 50% weight-loss injections 50% dating life 40% mental health 40%

Sentiment Analysis

Neutral

Score: 0.10

Source Transparency

Source

South China Morning Post

Political Lean

Center-Right (0.50)

Far LeftCenterFar Right

Classification Confidence

90%

Geographic Perspective

India

This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).

Topic Connections

Explore how the topics in this article connect to other news stories

Network visualization showing 15 related topics

View Full Graph

weight loss semaglutide weight-loss medication obesity price war patent expiration weight-loss injections dating life mental health

Explore Full Topic Graph

Find Similar Articles

AI-Powered

Discover articles with similar content using semantic similarity analysis.